Absci Corp
Research Absci Corp (ABSI) on Bullrun: market cap USD 1.77B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerABSI
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.77B
- Financial periodFY2025
- RevenueUSD 2.80M
- Revenue growth-38.2%
- Net income-USD 115.18M
- Free cash flow-USD 94.03M
Valuation Snapshot
latest market cap is USD 1.77B.
About Absci Corp
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Frequently asked questions
What is Absci Corp's market cap?
Absci Corp's market capitalization is USD 1.77B.
What does Absci Corp do?
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease;